CTKB RSI Chart
Last 7 days
-3.3%
Last 30 days
2.9%
Last 90 days
-28.4%
Trailing 12 Months
-9.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 200.8M | 0 | 0 | 0 |
2023 | 166.1M | 175.6M | 183.1M | 193.0M |
2022 | 138.7M | 148.5M | 154.6M | 164.0M |
2021 | 101.6M | 110.4M | 119.2M | 128.0M |
2020 | 0 | 0 | 0 | 92.8M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 19, 2024 | yan ming | sold | -117,400 | 5.87 | -20,000 | chief technology officer |
Apr 09, 2024 | yan ming | sold | -13,304 | 7.00211 | -1,900 | chief technology officer |
Mar 20, 2024 | busque philippe | acquired | - | - | 5,464 | svp, global sales and services |
Mar 20, 2024 | busque philippe | sold (taxes) | -14,264 | 6.7 | -2,129 | svp, global sales and services |
Mar 19, 2024 | yan ming | sold | -134,200 | 6.71 | -20,000 | chief technology officer |
Mar 18, 2024 | yan ming | sold | -135,400 | 6.77 | -20,000 | chief technology officer |
Mar 11, 2024 | poirson allen | sold (taxes) | -9,393 | 7.22 | -1,301 | svp bus. and corp. dev. |
Mar 11, 2024 | poirson allen | acquired | - | - | 3,338 | svp bus. and corp. dev. |
Mar 11, 2024 | barnett valerie | acquired | - | - | 4,908 | chief legal officer |
Mar 11, 2024 | jeanmonod patrik | sold (taxes) | -13,804 | 7.22 | -1,912 | chief financial officer |
Which funds bought or sold CTKB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | reduced | -9.44 | -137,503 | 274,566 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -10.94 | -387,265 | 736,100 | -% |
May 16, 2024 | Grandeur Peak Global Advisors, LLC | unchanged | - | -79,846 | 222,309 | 0.02% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -76.88 | -1,508,060 | 309,077 | -% |
May 15, 2024 | HSBC HOLDINGS PLC | new | - | 90,317 | 90,317 | -% |
May 15, 2024 | STATE STREET CORP | added | 2.95 | -8,842,240 | 27,617,400 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 155 | 280,405 | 599,651 | -% |
May 15, 2024 | Divisadero Street Capital Management, LP | new | - | 3,271,460 | 3,271,460 | 0.77% |
May 15, 2024 | WELLINGTON MANAGEMENT GROUP LLP | added | 4.93 | -2,684,420 | 9,091,850 | -% |
May 15, 2024 | MORGAN STANLEY | added | 0.88 | -1,965,720 | 5,660,030 | -% |
Unveiling Cytek Biosciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cytek Biosciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Cytek Biosciences, Inc. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Revenue | -23.0% | 44,860 | 58,234 | 48,000 | 49,693 | 37,088 | 48,336 | 40,477 | 40,159 | 35,064 | 38,894 | 34,376 | 30,408 | 24,272 | 24,684 | 25,096 | 19,136 |
Gross Profit | -30.4% | 23,013 | 33,048 | 27,178 | 28,162 | 21,038 | 29,374 | 26,862 | 24,561 | 20,177 | 23,636 | 21,277 | 19,745 | 14,486 | - | 15,616 | 8,270 |
Operating Expenses | 1.7% | 33,747 | 33,185 | 33,598 | 37,289 | 33,200 | 29,290 | 25,502 | 25,452 | 22,534 | 22,319 | 18,380 | 15,934 | 13,354 | - | 8,905 | 8,488 |
S&GA Expenses | 8.5% | 12,543 | 11,561 | 12,076 | 14,367 | 11,145 | 9,029 | 8,810 | 8,431 | 6,960 | 8,304 | 6,553 | 5,576 | 4,277 | - | 3,838 | 3,059 |
R&D Expenses | -9.9% | 9,796 | 10,870 | 11,171 | 12,136 | 9,974 | 9,747 | 8,650 | 8,436 | 8,025 | 7,076 | 6,078 | 6,194 | 5,094 | - | 3,376 | 2,916 |
EBITDA Margin | 10.4% | -0.04* | -0.04* | -0.04* | -0.02* | 0.01* | 0.04* | 0.02* | 0.02* | 0.05* | 0.07* | 0.13* | 0.14* | 0.15* | - | - | - |
Interest Expenses | 11.9% | 441 | 394 | 595 | 409 | 673 | 687 | 649 | 647 | 590 | 492 | 441 | 433 | 375 | - | 2.00 | 1.00 |
Income Taxes | -101.1% | -2,800 | -1,392 | 2,271 | -2,207 | -2,233 | 396 | 224 | -699 | -1,145 | 1,609 | 655 | 597 | 50.00 | - | 357 | -7,919 |
Earnings Before Taxes | -318.8% | -8,993 | 4,111 | -4,185 | -6,595 | -9,040 | 4,114 | 1,850 | -1,401 | -3,303 | 444 | 2,075 | 3,267 | 152 | - | 6,897 | 192 |
EBT Margin | 4.2% | -0.08* | -0.08* | -0.09* | -0.06* | -0.03* | 0.01* | -0.02* | -0.01* | 0.02* | 0.05* | 0.12* | 0.13* | 0.14* | - | - | - |
Net Income | -212.1% | -6,169 | 5,503 | -6,456 | -4,388 | -6,807 | 3,598 | 1,626 | -598 | -2,021 | -1,165 | 1,420 | 2,670 | 102 | 5,599 | 6,540 | 8,111 |
Net Income Margin | 8.9% | -0.06* | -0.06* | -0.08* | -0.03* | -0.01* | 0.02* | -0.01* | -0.02* | 0.01* | 0.02* | 0.08* | 0.14* | 0.20* | - | - | - |
Free Cashflow | -57.7% | 3,390 | 8,012 | -5,569 | -4,163 | 2,353 | -337 | -8,614 | -10,768 | -2,260 | 4,152 | -147 | -5,165 | 1,426 | - | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -0.5% | 492 | 494 | 519 | 525 | 525 | 519 | 499 | 493 | 486 | 463 | 454 | 230 | 220 |
Current Assets | -0.9% | 389 | 392 | 422 | 425 | 426 | 454 | 444 | 443 | 439 | 432 | 440 | 217 | 209 |
Cash Equivalents | 1.1% | 169 | 167 | 164 | 132 | 129 | 297 | 342 | 350 | 363 | 365 | 377 | 160 | 166 |
Inventory | -10.1% | 55.00 | 61.00 | 67.00 | 66.00 | 70.00 | 48.00 | 49.00 | 45.00 | 38.00 | 32.00 | 28.00 | 27.00 | 23.00 |
Net PPE | -0.9% | 18.00 | 18.00 | 17.00 | 16.00 | 16.00 | 14.00 | 8.00 | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 2.00 |
Goodwill | 0% | 16.00 | 16.00 | 16.00 | 19.00 | 19.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -1.9% | 99.00 | 101 | 104 | 101 | 101 | 94.00 | 83.00 | 82.00 | 78.00 | 58.00 | 51.00 | 47.00 | 42.00 |
Current Liabilities | -1.2% | 56.00 | 56.00 | 59.00 | 54.00 | 57.00 | 49.00 | 41.00 | 42.00 | 43.00 | 33.00 | 30.00 | 28.00 | 27.00 |
Shareholder's Equity | -0.1% | 393 | 393 | 416 | 424 | 423 | 426 | 417 | 411 | 407 | 405 | 403 | - | -16.03 |
Retained Earnings | -21.1% | -35.35 | -29.18 | -34.68 | -28.22 | -23.84 | -17.03 | -20.56 | -22.22 | -21.63 | -19.61 | -18.41 | -19.83 | -22.61 |
Additional Paid-In Capital | 1.4% | 429 | 423 | 452 | 454 | 448 | 443 | 437 | 433 | 428 | 424 | 421 | 8.00 | 6.00 |
Shares Outstanding | 0.4% | 131 | 131 | 136 | 136 | 136 | 135 | 135 | 134 | 134 | 77.00 | 58.00 | 32.00 | - |
Float | - | - | - | - | 1,030 | - | 1,300 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -58.4% | 3,957 | 9,512 | -4,239 | -2,850 | 2,858 | 6,193 | -7,504 | -9,440 | -1,480 | 5,448 | 1,161 | -3,914 | 1,935 | - | - | - |
Share Based Compensation | -0.5% | 5,640 | 5,669 | 5,758 | 5,922 | 4,699 | 4,465 | 4,359 | 3,934 | 3,837 | 3,008 | 2,455 | 667 | 456 | - | - | - |
Cashflow From Investing | -119.8% | -5,754 | 29,066 | 43,124 | 2,790 | -168,874 | -51,064 | -1,150 | -2,915 | -780 | -18,296 | -1,308 | -1,251 | -138 | - | - | - |
Cashflow From Financing | 104.8% | 1,613 | -33,754 | -8,274 | 216 | - | 3,850 | 155 | 1,144 | 364 | 17.00 | 217,078 | -3,723 | 187 | - | - | - |
Buy Backs | -100.0% | - | 34,600 | 8,428 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue, net: | ||
Total revenue, net | $ 44,860 | $ 37,088 |
Cost of sales: | ||
Total cost of sales | 21,847 | 16,050 |
Gross profit | 23,013 | 21,038 |
Operating expenses: | ||
Research and development | 9,796 | 9,974 |
Sales and marketing | 12,543 | 11,145 |
General and administrative | 11,408 | 12,081 |
Total operating expenses | 33,747 | 33,200 |
Loss from operations | (10,734) | (12,162) |
Other income (expense): | ||
Interest expense | (441) | (673) |
Interest income | 1,359 | 2,143 |
Other income, net | 823 | 1,652 |
Total other income, net | 1,741 | 3,122 |
Loss before income taxes | (8,993) | (9,040) |
Benefit from income taxes | (2,824) | (2,233) |
Net loss | (6,169) | (6,807) |
Net loss, basic | (6,169) | (6,807) |
Net loss, diluted | $ (6,169) | $ (6,807) |
Net loss per share, basic (in dollars per share) | $ (0.05) | $ (0.05) |
Net loss per share, diluted (in dollars per share) | $ (0.05) | $ (0.05) |
Weighted-average shares used in calculating net loss per share, basic (in shares) | 130,920,971 | 135,489,194 |
Weighted-average shares used in calculating net loss per share, diluted (in shares) | 130,920,971 | 135,489,194 |
Comprehensive loss: | ||
Net loss | $ (6,169) | $ (6,807) |
Foreign currency translation adjustment, net of tax | (244) | (42) |
Unrealized (loss) gain on marketable securities | (35) | 152 |
Net comprehensive loss | (6,448) | (6,697) |
Product | ||
Revenue, net: | ||
Total revenue, net | 34,122 | 31,172 |
Cost of sales: | ||
Total cost of sales | 16,746 | 12,677 |
Service | ||
Revenue, net: | ||
Total revenue, net | 10,738 | 5,916 |
Cost of sales: | ||
Total cost of sales | $ 5,101 | $ 3,373 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 168,788 | $ 167,299 |
Restricted cash | 353 | 331 |
Marketable securities | 101,298 | 95,111 |
Trade accounts receivable, net | 50,306 | 55,928 |
Inventories | 54,742 | 60,877 |
Prepaid expenses and other current assets | 13,160 | 12,514 |
Total current assets | 388,647 | 392,060 |
Deferred income tax assets, noncurrent | 32,708 | 30,487 |
Property and equipment, net | 18,247 | 18,405 |
Operating lease right-of-use assets | 9,949 | 10,853 |
Goodwill | 16,183 | 16,183 |
Intangible assets, net | 22,252 | 23,084 |
Other noncurrent assets | 4,081 | 3,385 |
Total assets | 492,067 | 494,457 |
Current liabilities: | ||
Trade accounts payable | 3,725 | 3,032 |
Legal settlement liability, current | 2,550 | 2,561 |
Accrued expenses | 18,054 | 20,035 |
Other current liabilities | 8,228 | 7,903 |
Deferred revenue, current | 23,009 | 22,695 |
Total current liabilities | 55,566 | 56,226 |
Legal settlement liability, noncurrent | 16,722 | 16,477 |
Deferred revenue, noncurrent | 15,164 | 15,132 |
Operating lease liability, noncurrent | 8,697 | 9,479 |
Long term debt | 1,477 | 1,648 |
Other noncurrent liabilities | 1,827 | 2,431 |
Total liabilities | 99,453 | 101,393 |
Commitments and contingencies (Note 18) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of March 31, 2024 and December 31, 2023, respectively; 131,254,181 and 130,714,906 issued and outstanding shares as of March 31, 2024 and December 31, 2023, respectively. | 131 | 131 |
Additional paid-in capital | 429,384 | 423,386 |
Accumulated deficit | (35,347) | (29,178) |
Accumulated other comprehensive loss | (1,554) | (1,275) |
Total stockholders’ equity | 392,614 | 393,064 |
Total liabilities and stockholders’ equity | $ 492,067 | $ 494,457 |